A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

NCT07111832 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer

Interventions

DRUG: SHR-A1811 for Injection
DRUG: SHR-1316 Injection
DRUG: Toripalimab Injection
DRUG: Paclitaxel for Injection

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.